Wikisage, the free encyclopedia of the second generation, is digital heritage

Eslicarbazepine: Difference between revisions

From Wikisage
Jump to navigation Jump to search
m (todo rufinamide)
 
(6 intermediate revisions by the same user not shown)
Line 1: Line 1:
[[File:1Eslicarbazepine acetate structure.svg.png|thumb]]
[[File:1Eslicarbazepine acetate structure.svg.png|thumb]]


S-licarbazepine is an [[antiepileptic drug|AED]]. Adjunctive eslicarbazepine led to seizure reduction in patients with severe myoclonic [[epilepsy]] of infancy<ref>Severe myoclonic epilepsy of infancy: Seizure reduction during adjunctive eslicarbazepine in two cases</ref><ref>[http://onlinelibrary.wiley.com/doi/10.1111/epi.12894/epdf Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial]</ref>
S-licarbazepine is an [[antiepileptic drug|AED]]. Adjunctive eslicarbazepine led to seizure reduction in patients with severe myoclonic [[epilepsy]] of infancy<ref>[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4501557/pdf/main.pdf Severe myoclonic epilepsy of infancy: Seizure reduction during adjunctive eslicarbazepine in two cases]</ref><ref>[http://onlinelibrary.wiley.com/doi/10.1111/epi.12894/epdf Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial]</ref>


==Pharmacy and chemistry==
==Pharmacy and chemistry==


Eslicarbamazepine acetate is an once-daily antiepileptic that was approved in 2009 by the [[European Medicines Agency|EMA]] (Zerebix <sup>TM</sup>) and recently by the American [[FDA]]<ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480532/pdf/10.1177_1756285615589711.pdf A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures]</ref>
Eslicarbamazepine acetate is an once-daily antiepileptic that was approved in 2009 by the [[European Medicines Agency|EMA]] (Zerebix <sup>TM</sup>) and recently by the American [[FDA]]<ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480532/pdf/10.1177_1756285615589711.pdf A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures]</ref>
Eslicarbamazepine is the prodrug of S-licarbazepine, both oxcarbazapine and eslicarbazepine metabolize same, different to carbazepine; the latter metabolizes to CBZ 10,11-epoxide (Hainzl et al, 2001)<ref>https://www.dovepress.com/clinical-utility-of-eslicarbazepine-current-evidence-peer-reviewed-article-DDDT</ref>
Eslicarbamazepine is the prodrug of S-licarbazepine, both oxcarbazapine and eslicarbazepine metabolize same, different to [[carbazepine]]; the latter metabolizes to CBZ 10,11-epoxide (Hainzl et al, 2001)<ref>https://www.dovepress.com/clinical-utility-of-eslicarbazepine-current-evidence-peer-reviewed-article-DDDT</ref>


==Pharmacology==
==Pharmacology==
Line 18: Line 18:
*[[rufinamide]]
*[[rufinamide]]
*felbamate
*felbamate
*lamotrigine
*[[lamotrigine]]
*oxcarbazepine
*[[oxcarbazepine]]
*topiramate
*[[topiramate]]
*vigabatrin
*vigabatrin
*[[valproic acid|VPA]]
*[[valproic acid|VPA]]


<ref>[http://apps.elsevier.es/watermark/ctl_servlet?_f=10&pident_articulo=90431353&pident_usuario=0&pcontactid=&pident_revista=486&ty=55&accion=L&origen=zonadelectura&web=www.elsevier.es&lan=en&fichero=486v08n02a90431353pdf001.pdf The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part I: A summary of the current state for clinicians ]</ref>
<ref>[http://apps.elsevier.es/watermark/ctl_servlet?_f=10&pident_articulo=90431353&pident_usuario=0&pcontactid=&pident_revista=486&ty=55&accion=L&origen=zonadelectura&web=www.elsevier.es&lan=en&fichero=486v08n02a90431353pdf001.pdf The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part I: A summary of the current state for clinicians ]</ref>
===Cutaneous adverse effects===
===Cutaneous adverse effects===
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231563/ Cutaneous adverse drug reaction type erythema multiforme major induced by eslicarbazepine]
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231563/ Cutaneous adverse drug reaction type erythema multiforme major induced by eslicarbazepine]
Line 35: Line 36:
|}
|}


[[File:Wikidata-logo-en.svg.png|32px]]
{{Wikidata|Q410273}}
[https://www.wikidata.org/wiki/Q410273 Q410273]


==Bioquivalence==
==Bioequivalence==
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689905/pdf/40268_2013_Article_16.pdf Bioequivalence of eslicarbazepine acetate from two different sources of its active product ingredient in healthy subjects]
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689905/pdf/40268_2013_Article_16.pdf Bioequivalence of eslicarbazepine acetate from two different sources of its active product ingredient in healthy subjects]



Latest revision as of 19:17, 13 October 2017

S-licarbazepine is an AED. Adjunctive eslicarbazepine led to seizure reduction in patients with severe myoclonic epilepsy of infancy[1][2]

Pharmacy and chemistry

Eslicarbamazepine acetate is an once-daily antiepileptic that was approved in 2009 by the EMA (Zerebix TM) and recently by the American FDA[3] Eslicarbamazepine is the prodrug of S-licarbazepine, both oxcarbazapine and eslicarbazepine metabolize same, different to carbazepine; the latter metabolizes to CBZ 10,11-epoxide (Hainzl et al, 2001)[4]

Pharmacology

Mild inducers

After de Leon the following AED groups as mild inducers:

[5]

Cutaneous adverse effects

Cutaneous adverse drug reaction type erythema multiforme major induced by eslicarbazepine

ATC code N03

eslicarbazepine
[6]

Q410273 at Wikidata  Interwiki via Wikidata


Bioequivalence

Bioequivalence of eslicarbazepine acetate from two different sources of its active product ingredient in healthy subjects

References